TIDMFDBK

RNS Number : 3158R

Feedback PLC

25 October 2023

25 October 2023

Feedback plc

Director/PDMR Dealing

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, was informed on 24 October 2023 that on 7 September 2023, 5,422 ordinary shares of 50 pence each in capital of the Company ("Ordinary Shares") held by Annemijn Eschauzier, Non-Executive Director of the Company, were inadvertently sold at a price of 87.1 pence per Ordinary Share. This sale was made inadvertently due to a clerical error by the administrator of Annemijn Eschauzier's investment account during a transition of Annemijn Eschauzier's wider investment portfolio. Annemijn Eschauzier did not provide instruction for this sale to take place. Annemijn Eschauzier intends to repurchase the 5,422 Ordinary Shares.

Following this sale of Ordinary Shares, Annemijn Eschauzier holds an interest in 18 Ordinary Shares in the Company, representing 0.00% of the Company's issued share capital.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Names                                  Annemijn Eschauzier 
      -------------------------------------  --------------------------------------------------- 
       Reason for the notification 
  2 
      ------------------------------------------------------------------------------------------ 
 a)    Position/status                        Non-Executive Director 
      -------------------------------------  --------------------------------------------------- 
 b)    Initial notification                   Initial notification 
        /Amendment 
      -------------------------------------  --------------------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------------------ 
 a)    Name                                   Feedback plc 
      -------------------------------------  --------------------------------------------------- 
 b)    LEI                                    213800UGOF2GT2U2RV90 
      -------------------------------------  --------------------------------------------------- 
       Details of the transaction(s): section to be repeated 
  4     for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------------------------ 
 a)    Description of                         Ordinary Shares of 50 pence each in Feedback 
        the financial                          plc 
        instrument, type 
        of instrument 
 
       Identification                         GB00BJN59X09 
        code 
      -------------------------------------  --------------------------------------------------- 
 b)    Nature of the                          Sale of Ordinary Shares 
        transaction 
      -------------------------------------  --------------------------------------------------- 
 c)    Price(s) and volume(s) 
                                              -------------------------  --------------------- 
                                               Price(s)                   Volume(s) 
                                              -------------------------  --------------------- 
    87.1 pence                                                            5,422 
   --------------------------------------------------------------------  --------------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                    n/a 
 
  - Price 
 
 e)    Date of the transaction                7 September 2023 
      -------------------------------------  --------------------------------------------------- 
 f)    Place of the transaction               XLON 
      -------------------------------------  --------------------------------------------------- 
 

- Ends -

Enquiries:

 
 Feedback plc                             +44 (0) 20 3997 7634 
  Tom Oakley, CEO                          IR@fbk.com 
  Anesh Patel, CFO 
 
 Panmure Gordon (UK) Limited (NOMAD 
  and Broker) 
  Emma Earl/Freddy Crossley (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking)      +44 (0)20 7886 2500 
 
 Walbrook PR Ltd;                         Tel: 020 7933 8780 or feedbackplc@walbrookpr.com 
 Nick Rome/Joe Walker                     07748 325 236 or 07407 020 
                                           470 
 

About Feedback

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment.

Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHPPGUAUUPWGQA

(END) Dow Jones Newswires

October 25, 2023 12:53 ET (16:53 GMT)

Feedback (LSE:FDBK)
過去 株価チャート
から 11 2024 まで 12 2024 Feedbackのチャートをもっと見るにはこちらをクリック
Feedback (LSE:FDBK)
過去 株価チャート
から 12 2023 まで 12 2024 Feedbackのチャートをもっと見るにはこちらをクリック